Introducing the Neotherix Team

Dr Rod Adams, Chairman

Rod Adams

After graduating, Rod worked for a number of pharmaceutical companies before forming his own company, Adams Healthcare, following a management buyout from Depuy International in 1997.

Adams Healthcare specialised in Infection Control and Dermatological products covering liquids (including flammables), ointments and creams, supplying every hospital (private and public) in the UK. In May 2002, Medical Solutions Ltd acquired the company with Rod becoming COO of the new group as well as continuing in his role as MD of Adams Healthcare. In December 2002 he sold the Adams Healthcare Division of Medical Solutions Ltd to Ecolab Inc, becoming European Projects Director for the company until 2004.

Rod was appointed to the Board of Syntopix Ltd, a dermatological drug R&D company in October 2004. He was appointed CEO in November 2005 to lead the successful flotation of the company onto the AIM market, which occurred in March 2006. In January 2007 Rod became Chairman of Syntopix Group Plc.

Dr Adams co-founded Neoceuticals to develop paediatric and specialist nutritional products in 2007 and was appointed Chairman of Cizzle Biotechnology Ltd in the same year.

Rod’s extensive experience has helped guide Neotherix from spin-out to the verge of scale-up.

Dr Mike Raxworthy, Founder and Chief Executive Officer

Dr Mike Raxworthy

Mike Raxworthy is a biomedical scientist and holds a PhD from the University of Leeds. He has over 33 years’ experience leading research and development projects in the medical technology, medical device and pharmaceutical industries, having held senior roles at Smith & Nephew and 3M Health Care. His first involvement in tissue engineering/regenerative medicine was in 1996. He holds an MBA from Warwick Business School and is also the founder of Neotherix, which he spun-out from Smith & Nephew in 2007 to focus on bioresorbable regenerative scaffolds for tissue repair. Mike combines Neotherix responsibilities with those of Associate Professor in Engineering Management and Innovation at the University of Leeds. He was a Royal Academy of Engineering Visiting Professor in Medical Technology Innovation and Translation at Leeds from 2015-2018.

Mike’s background has provided an understanding of the workings of large and micro companies as well as extensive experience of the public sector through business engagement and education roles at Leeds. Many lessons on the challenges of MedTech translation from lab to market have been learned (and are still being learned) along the way. He has a strong interest in entrepreneurship and the innovation process and in selecting and developing the most promising ideas and concepts using appropriate decision criteria. He has recently been able to apply this interest to the translation of MedTech in low-resource settings and is the Principal Investigator for a Global Challenges Research Fund project focusing on biomedical engineering in East Africa.

Dr Ramisha Rehman, Translational Projects Manager

Ramisha holds a PhD from the University of Bradford in Medical and Healthcare Technologies which focused on areas of cellular response to surface characterisation and the development of regenerative scaffolds. Ramisha moved to Neotherix in 2019 from the University of Leeds where she worked as a Curriculum Development Officer, developing CPD accredited MedTech programs.

Her role at Neotherix is to oversee the progression of the most attractive product opportunities in our portfolio through the translation process.

Susan Proctor, Interim Finance Director

Sue Proctor

Sue Proctor BSc FCA is a Fellow of the Institute of Chartered Accountants in England and Wales. She has an extensive financial background through experience of roles with KPMG, ICIS Technology (a subsidiary of Siemens) and was formerly Finance Director at Xceleron in York.